| Year |
Citation |
Score |
| 2016 |
Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Kyle RA, Russell S, Lust JA, ... ... Zeldenrust S, et al. Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation. American Journal of Hematology. PMID 27341539 DOI: 10.1002/Ajh.24453 |
0.316 |
|
| 2012 |
Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 119: 4860-7. PMID 22504925 DOI: 10.1182/Blood-2012-01-407791 |
0.302 |
|
| 2012 |
Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 119: 5397-404. PMID 22493299 DOI: 10.1182/Blood-2012-02-413161 |
0.321 |
|
| 2006 |
Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, ... ... Zeldenrust SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 107: 3378-83. PMID 16397135 DOI: 10.1182/Blood-2005-07-2922 |
0.324 |
|
| 2003 |
Sharma P, Perri RE, Sirven JE, Zeldenrust SR, Brandhagen DJ, Rosen CB, Douglas DD, Mulligan DC, Rakela J, Wiesner RH, Balan V. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 9: 1273-80. PMID 14625827 DOI: 10.1016/j.lts.2003.09.016 |
0.318 |
|
| 1994 |
Zeldenrust SR, Skinner M, Share J, Benson MD. A new transthyretin variant (his 69) associated with vitreous amyloid in an FAP family Amyloid. 1: 17-22. DOI: 10.3109/13506129409148620 |
0.328 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, ... ... Zeldenrust S, et al. Improved outcomes for newly diagnosed AL amyloidosis over the years 2000-2014: cracking the glass ceiling of early death. Blood. PMID 28126928 DOI: 10.1182/Blood-2016-11-751628 |
0.298 |
|
| 2016 |
Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, Zeldenrust SR, Zenka RM, Dogan A, Dispenzieri A. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light chain amyloidosis by mass spectrometry. Blood. PMID 27856462 DOI: 10.1182/Blood-2016-10-743997 |
0.296 |
|
| 2014 |
Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, et al. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology. 89: 302-5. PMID 24265187 DOI: 10.1002/Ajh.23634 |
0.296 |
|
| 2017 |
Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, et al. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology. PMID 28699650 DOI: 10.1111/Bjh.14830 |
0.294 |
|
| 2015 |
Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology. 90: 181-6. PMID 25388651 DOI: 10.1002/Ajh.23898 |
0.293 |
|
| 2019 |
Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, ... ... Zeldenrust S, et al. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 1-4. PMID 31544536 DOI: 10.1080/13506129.2019.1666709 |
0.292 |
|
| 2020 |
Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, ... ... Zeldenrust S, et al. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal. 10: 4. PMID 31913261 DOI: 10.1038/S41408-019-0266-9 |
0.289 |
|
| 2017 |
Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, et al. Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma. American Journal of Hematology. PMID 29067723 DOI: 10.1002/Ajh.24954 |
0.289 |
|
| 2012 |
D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 120: 56-62. PMID 22611150 DOI: 10.1182/blood-2012-04-423178 |
0.287 |
|
| 2014 |
Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology. 92: 485-90. PMID 24502602 DOI: 10.1111/Ejh.12282 |
0.286 |
|
| 2006 |
Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle & Nerve. 33: 609-18. PMID 16421881 DOI: 10.1002/Mus.20503 |
0.286 |
|
| 2013 |
Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, Kumar S. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia. 27: 2062-6. PMID 23648667 DOI: 10.1038/leu.2013.143 |
0.286 |
|
| 2017 |
Ghosh T, Gonsalves WI, Jevremovic D, Dispenzieri A, Dingli D, Timm MM, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, ... ... Zeldenrust SR, et al. The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Relapsing Multiple Myeloma. American Journal of Hematology. PMID 28568244 DOI: 10.1002/Ajh.24807 |
0.285 |
|
| 2018 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, ... ... Zeldenrust SR, et al. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia. PMID 29483709 DOI: 10.1038/S41375-018-0063-7 |
0.285 |
|
| 2008 |
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111: 2516-20. PMID 17975015 DOI: 10.1182/Blood-2007-10-116129 |
0.283 |
|
| 2004 |
Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, ... ... Zeldenrust SR, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 104: 1881-7. PMID 15044258 DOI: 10.1182/Blood-2004-01-0390 |
0.283 |
|
| 2016 |
Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russel S, Lust JA, Lin Y, Go RS, Zeldenrust S, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. PMID 27479823 DOI: 10.3324/Haematol.2016.147041 |
0.283 |
|
| 2007 |
Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 109: 465-70. PMID 17008538 DOI: 10.1182/Blood-2006-07-032987 |
0.282 |
|
| 2013 |
Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica. 98: 988-92. PMID 23729727 DOI: 10.3324/Haematol.2012.079210 |
0.282 |
|
| 2019 |
Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, ... ... Zeldenrust S, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology. PMID 31298751 DOI: 10.1111/Bjh.16096 |
0.281 |
|
| 2019 |
Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, ... ... Zeldenrust S, et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. PMID 31758090 DOI: 10.1038/S41375-019-0655-X |
0.281 |
|
| 2012 |
Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, et al. Immunoglobulin D amyloidosis: a distinct entity. Blood. 119: 44-8. PMID 22065594 DOI: 10.1182/Blood-2011-06-358895 |
0.281 |
|
| 2017 |
Tandon N, Sidana S, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Kyle RA, Buadi FK, Dingli D, Hayman SR, Fonder AL, Hobbs MA, Gonsalves WI, Kapoor P, Hwa YL, ... ... Zeldenrust SR, et al. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 1-6. PMID 28699793 DOI: 10.1080/13506129.2017.1351354 |
0.28 |
|
| 2004 |
Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 103: 3960-3. PMID 14739213 DOI: 10.1182/Blood-2003-12-4192 |
0.28 |
|
| 2013 |
Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, et al. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology. 88: 375-8. PMID 23508840 DOI: 10.1002/ajh.23413 |
0.28 |
|
| 2010 |
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 116: 5126-9. PMID 20798235 DOI: 10.1182/Blood-2010-06-290668 |
0.278 |
|
| 2018 |
Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, et al. Analysis of Clinical Factors and Outcomes Associated with Non-Utilization of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29656139 DOI: 10.1016/J.Bbmt.2018.04.007 |
0.274 |
|
| 2014 |
Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 124: 907-12. PMID 24957143 DOI: 10.1182/Blood-2014-03-565051 |
0.272 |
|
| 2011 |
Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology. 86: 251-5. PMID 21328431 DOI: 10.1002/Ajh.21948 |
0.272 |
|
| 2017 |
Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Zeldenrust SR, et al. Treatment Patterns and Outcome Following Initial Relapse or Refractory Disease in Patients with Systemic Light Chain Amyloidosis. American Journal of Hematology. PMID 28314084 DOI: 10.1002/Ajh.24723 |
0.27 |
|
| 2016 |
Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, Kapoor P, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology. PMID 27501122 DOI: 10.1002/Ajh.24528 |
0.267 |
|
| 2018 |
Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal. 8: 125. PMID 30538223 DOI: 10.1038/S41408-018-0163-7 |
0.265 |
|
| 2016 |
Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, ... Zeldenrust S, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first line treatment. Blood. PMID 27729322 DOI: 10.1182/Blood-2016-06-721878 |
0.265 |
|
| 2018 |
Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, et al. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology. PMID 29659048 DOI: 10.1002/Ajh.25113 |
0.265 |
|
| 1994 |
Zeldenrust SR, Bensonf MD. A new test for detection ot the his 58 variant transthyretin allele in hereditary amyloidosis; creation of diagnostic restriction endonuclease recognition sites by PCR based mutagenesis Amyloid. 1: 154-159. DOI: 10.3109/13506129409148446 |
0.263 |
|
| 2013 |
Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 122: 4172-81. PMID 24144641 DOI: 10.1182/Blood-2013-08-520890 |
0.263 |
|
| 2010 |
Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. American Journal of Hematology. 85: 737-40. PMID 20730790 DOI: 10.1002/Ajh.21821 |
0.26 |
|
| 2009 |
Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Current Hematologic Malignancy Reports. 4: 91-8. PMID 20425420 DOI: 10.1007/s11899-009-0013-6 |
0.26 |
|
| 2014 |
Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. The American Journal of Cardiology. 113: 1723-7. PMID 24698461 DOI: 10.1016/j.amjcard.2014.02.030 |
0.259 |
|
| 2012 |
Zeldenrust SR. Genotype--phenotype correlation in FAP. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 19: 22-4. PMID 22620962 DOI: 10.3109/13506129.2012.665400 |
0.259 |
|
| 2016 |
Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, et al. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology. PMID 26972803 DOI: 10.1002/Ajh.24356 |
0.256 |
|
| 2015 |
Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, Lin Y, Russell S, Hwa L, Kapoor P, Go RS, ... Zeldenrust SR, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer Journal. 5: e310. PMID 25933374 DOI: 10.1038/bcj.2015.34 |
0.254 |
|
| 2010 |
Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, ... ... Zeldenrust SR, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clinic Proceedings. 85: 824-33. PMID 20702770 DOI: 10.4065/Mcp.2010.0304 |
0.253 |
|
| 2010 |
Chee CE, Lacy MQ, Dogan A, Zeldenrust SR, Gertz MA. Pitfalls in the diagnosis of primary amyloidosis. Clinical Lymphoma, Myeloma & Leukemia. 10: 177-80. PMID 20511161 DOI: 10.3816/CLML.2010.n.027 |
0.253 |
|
| 2014 |
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28: 1122-8. PMID 24157580 DOI: 10.1038/Leu.2013.313 |
0.252 |
|
| 2010 |
Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 24: 1934-9. PMID 20827286 DOI: 10.1182/Blood.V114.22.429.429 |
0.252 |
|
| 2009 |
Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, ... ... Zeldenrust SR, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 114: 518-21. PMID 19324902 DOI: 10.1182/Blood-2009-01-202010 |
0.252 |
|
| 2015 |
Swiecicki PL, Zhen DB, Mauermann ML, Kyle RA, Zeldenrust SR, Grogan M, Dispenzieri A, Gertz MA. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 22: 123-31. PMID 26017327 DOI: 10.3109/13506129.2015.1019610 |
0.251 |
|
| 2011 |
Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 118: 1763-5. PMID 21673347 DOI: 10.1182/Blood-2011-04-350009 |
0.251 |
|
| 2011 |
Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. American Journal of Hematology. 86: 640-5. PMID 21630308 DOI: 10.1002/Ajh.22053 |
0.25 |
|
| 2014 |
Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology. 89: 1051-4. PMID 25111004 DOI: 10.1002/Ajh.23827 |
0.25 |
|
| 2011 |
Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology. 90: 101-6. PMID 20645101 DOI: 10.1007/S00277-010-1028-8 |
0.25 |
|
| 2016 |
Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma Blood Cancer Journal. 6. DOI: 10.1038/bcj.2016.15 |
0.25 |
|
| 2015 |
Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. American Journal of Hematology. 90: 524-8. PMID 25753178 DOI: 10.1002/Ajh.24001 |
0.249 |
|
| 2010 |
Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, Kumar SK. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clinic Proceedings. 85: 232-8. PMID 20194151 DOI: 10.1182/Blood.V114.22.4867.4867 |
0.245 |
|
| 2007 |
Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, ... Zeldenrust SR, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings. 82: 323-41. PMID 17352369 DOI: 10.4065/82.3.323 |
0.242 |
|
| 2011 |
Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML, Bergen HR, Zeldenrust SR, Dogan A. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Archives of Neurology. 68: 195-9. PMID 20937937 DOI: 10.1001/Archneurol.2010.261 |
0.241 |
|
| 2012 |
Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 119: 2100-5. PMID 22234687 DOI: 10.1182/Blood-2011-11-390658 |
0.24 |
|
| 2006 |
Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. British Journal of Haematology. 133: 158-64. PMID 16611306 DOI: 10.1111/J.1365-2141.2006.06003.X |
0.237 |
|
| 2012 |
Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clinical Journal of the American Society of Nephrology : Cjasn. 7: 1964-8. PMID 23024162 DOI: 10.2215/Cjn.11161111 |
0.237 |
|
| 2017 |
Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Russell S, Kapoor P, Go RS, Kourelis T, Gonsalves W, ... Zeldenrust SR, et al. Hematology Patient Reported Symptom Screen to Assess Quality of Life for AL Amyloidosis. American Journal of Hematology. PMID 28181278 DOI: 10.1002/Ajh.24676 |
0.235 |
|
| 2007 |
Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 21: 529-34. PMID 17230230 DOI: 10.1038/sj.leu.2404516 |
0.235 |
|
| 2018 |
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, ... ... Zeldenrust SR, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal. 8: 59. PMID 29895887 DOI: 10.1038/S41408-018-0077-4 |
0.235 |
|
| 2010 |
Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 115: 1343-50. PMID 20008302 DOI: 10.1182/Blood-2009-08-239046 |
0.235 |
|
| 2019 |
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, ... ... Zeldenrust SR, et al. Impact of acquired del(17p) in multiple myeloma. Blood Advances. 3: 1930-1938. PMID 31248884 DOI: 10.1182/Bloodadvances.2018028530 |
0.234 |
|
| 2016 |
Milani P, Rajkumar SV, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, ... ... Zeldenrust SR, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology. PMID 27508522 DOI: 10.1002/Ajh.24532 |
0.234 |
|
| 2019 |
Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, et al. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia & Lymphoma. 1-8. PMID 31096812 DOI: 10.1080/10428194.2019.1613536 |
0.233 |
|
| 2013 |
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings. 88: 360-76. PMID 23541011 DOI: 10.1016/j.mayocp.2013.01.019 |
0.231 |
|
| 2016 |
Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA, Donovan KA. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. American Journal of Hematology. PMID 26945843 DOI: 10.1002/Ajh.24352 |
0.231 |
|
| 2017 |
Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hwa YL, Leung N, Fonder AL, Hobbs MA, ... Zeldenrust SR, et al. Clinical Presentation and Outcomes of Patients with Type 1 Monoclonal Cryoglobulinemia. American Journal of Hematology. PMID 28370486 DOI: 10.1002/Ajh.24745 |
0.23 |
|
| 2006 |
Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 108: 3458-64. PMID 16840727 DOI: 10.1182/Blood-2006-04-015909 |
0.228 |
|
| 2017 |
Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS. Ocular Manifestations of Familial Transthyretin Amyloidosis. American Journal of Ophthalmology. PMID 28911993 DOI: 10.1016/j.ajo.2017.09.001 |
0.227 |
|
| 2016 |
Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, et al. Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology. PMID 26840395 DOI: 10.1002/Ajh.24319 |
0.227 |
|
| 2009 |
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 94: 380-6. PMID 19211640 DOI: 10.3324/Haematol.13369 |
0.226 |
|
| 2010 |
Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology. 85: 757-9. PMID 20872958 DOI: 10.1002/Ajh.21822 |
0.226 |
|
| 2019 |
Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, ... ... Zeldenrust S, et al. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clinic Proceedings. PMID 30770096 DOI: 10.1016/j.mayocp.2018.08.006 |
0.223 |
|
| 2019 |
Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, et al. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology. PMID 30945330 DOI: 10.1002/ajh.25481 |
0.222 |
|
| 2015 |
Zhen DB, Swiecicki PL, Zeldenrust SR, Dispenzieri A, Mauermann ML, Gertz MA. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. Clinical Genetics. 88: 396-400. PMID 25211232 DOI: 10.1111/cge.12500 |
0.221 |
|
| 2012 |
Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, Kumar SK, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. American Journal of Hematology. 87: 647-51. PMID 22549792 DOI: 10.1002/Ajh.23201 |
0.22 |
|
| 2019 |
Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. PMID 30787429 DOI: 10.1038/S41375-019-0419-7 |
0.22 |
|
| 2011 |
Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clinic Proceedings. 86: 12-8. PMID 21193650 DOI: 10.4065/Mcp.2010.0480 |
0.217 |
|
| 2015 |
Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, ... ... Zeldenrust SR, et al. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clinic Proceedings. 90: 1054-81. PMID 26250727 DOI: 10.1016/j.mayocp.2015.06.009 |
0.217 |
|
| 2019 |
Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, et al. Substratification of patients with newly diagnosed standard-risk multiple myeloma. British Journal of Haematology. PMID 30768679 DOI: 10.1111/Bjh.15800 |
0.215 |
|
| 2006 |
Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic Proceedings. 81: 1047-53. PMID 16901028 DOI: 10.4065/81.8.1047 |
0.214 |
|
| 2008 |
Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney International. 73: 1282-8. PMID 18385667 DOI: 10.1038/ki.2008.108 |
0.213 |
|
| 2013 |
Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 122: 68-73. PMID 23699599 DOI: 10.1182/Blood-2013-03-487025 |
0.213 |
|
| 2015 |
Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first line treatment. Leukemia. PMID 26669974 DOI: 10.1038/Leu.2015.344 |
0.213 |
|
| 2011 |
Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 26: 2032-6. PMID 21543655 DOI: 10.1093/ndt/gfr067 |
0.213 |
|
| 2006 |
Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 107: 3669-75. PMID 16373658 DOI: 10.1182/Blood-2005-09-3810 |
0.212 |
|
| 2013 |
D'Souza A, Theis J, Quint P, Kyle R, Gertz M, Zeldenrust S, Vrana J, Dogan A, Dispenzieri A. Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry American Journal of Hematology. 88: 577-580. PMID 23606017 DOI: 10.1002/ajh.23456 |
0.211 |
|
| 2020 |
Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, ... ... Zeldenrust S, et al. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal. 10: 20. PMID 32098948 DOI: 10.1038/S41408-020-0291-8 |
0.211 |
|
| 2019 |
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, ... ... Zeldenrust SR, et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal. 9: 32. PMID 30846679 DOI: 10.1038/S41408-019-0191-Y |
0.21 |
|
| 2009 |
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, ... ... Zeldenrust SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clinic Proceedings. 84: 1095-110. PMID 19955246 DOI: 10.4065/Mcp.2009.0603 |
0.21 |
|
| 2014 |
Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, Grogan M, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Leung N, Russell SR, Dingli D, Lust JA, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart (British Cardiac Society). 100: 383-8. PMID 24402772 DOI: 10.1136/Heartjnl-2013-304957 |
0.208 |
|
| 2007 |
Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clinic Proceedings. 82: 1179-84. PMID 17908524 DOI: 10.4065/82.10.1179 |
0.207 |
|
| 1993 |
Zeldenrust SR, Murrell J, Farlow M, Ghetti B, Roses AD, Benson MD. RFLP analysis for APP 717 mutations associated with Alzheimer's disease. Journal of Medical Genetics. 30: 476-8. PMID 7686976 |
0.207 |
|
| 2009 |
Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 24: 3132-7. PMID 19403931 DOI: 10.1093/ndt/gfp201 |
0.205 |
|
| 2008 |
Kaplan B, Ramirez-Alvarado M, Dispenzieri A, Zeldenrust SR, Leung N, Livneh A, Gallo G. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 46: 335-41. PMID 18254719 DOI: 10.1515/Cclm.2008.068 |
0.205 |
|
| 2014 |
Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kurtin PJ, Grogg KL, Dogan A. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 99: 1239-47. PMID 24747948 DOI: 10.3324/haematol.2013.102764 |
0.201 |
|
| 2005 |
Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 106: 4050-3. PMID 16118317 DOI: 10.1182/Blood-2005-07-2817 |
0.2 |
|
| 2017 |
Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 24: 44-45. PMID 28434304 DOI: 10.1080/13506129.2017.1281117 |
0.2 |
|
| 2008 |
Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM, Tschumper RC, Wu X, Zeldenrust SR, Jelinek DF. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 112: 1931-41. PMID 18567838 DOI: 10.1182/Blood-2008-03-143040 |
0.197 |
|
| 2019 |
Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, ... ... Zeldenrust S, et al. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma & Leukemia. PMID 31685378 DOI: 10.1016/J.Clml.2019.09.624 |
0.196 |
|
| 2003 |
Bergen HR, Zeldenrust SR, Naylor S. An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 10: 190-7. PMID 14640032 |
0.196 |
|
| 2016 |
Gonsalves WI, Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa YL, et al. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplantation. PMID 27064687 DOI: 10.1038/bmt.2016.91 |
0.194 |
|
| 2012 |
Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal. 164: 222-228.e1. PMID 22877808 DOI: 10.1016/J.Ahj.2012.04.015 |
0.192 |
|
| 2011 |
Klein CJ, Moon JS, Mauermann ML, Zeldenrust SR, Wu Y, Dispenzieri A, Dyck PJ. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 38: 289-95. PMID 21320835 DOI: 10.1017/S0317167100011483 |
0.192 |
|
| 2013 |
Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4319-24. PMID 24145344 DOI: 10.1200/Jco.2013.50.8499 |
0.191 |
|
| 2015 |
Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, et al. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 26627634 DOI: 10.1093/Ndt/Gfv328 |
0.189 |
|
| 2012 |
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 989-95. PMID 22331953 DOI: 10.1200/Jco.2011.38.5724 |
0.189 |
|
| 2017 |
Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 24: 40-41. PMID 28434371 DOI: 10.1080/13506129.2016.1277696 |
0.188 |
|
| 2018 |
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, ... ... Zeldenrust S, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. PMID 29581546 DOI: 10.1038/S41375-018-0060-X |
0.188 |
|
| 2008 |
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV, Gertz MA. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clinic Proceedings. 83: 297-303. PMID 18315995 DOI: 10.4065/83.3.297 |
0.185 |
|
| 2004 |
Bergen HR, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Dyck PJ, Klein CJ, O'Brien JF, Thibodeau SN, Muddiman DC. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clinical Chemistry. 50: 1544-52. PMID 15217993 DOI: 10.1373/Clinchem.2004.033266 |
0.184 |
|
| 2004 |
Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3751-7. PMID 15365071 DOI: 10.1200/Jco.2004.03.029 |
0.183 |
|
| 2013 |
Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. Jama. 310: 2658-67. PMID 24368466 DOI: 10.1001/Jama.2013.283815 |
0.183 |
|
| 2012 |
Stangou AJ, Lobato L, Zeldenrust S, Rela M, Portmann B, Linke RP, Conceicao I, Otto G, Wilczek H, Suhr O, Azoulay D, Grateau G, Picken M, O'Grady J, Heaton N, et al. Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 19: 81-4. PMID 22540225 DOI: 10.3109/13506129.2012.668503 |
0.182 |
|
| 2013 |
Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, Gertz MA, Miller FA, Bielinski SJ, Klarich KW, Scott CG, Grogan M. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 20: 263-8. PMID 24131106 DOI: 10.3109/13506129.2013.845745 |
0.18 |
|
| 2017 |
Kourelis TV, Kyle RA, Dingli D, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Kapoor P, Go RS, Gonsalves WI, Warsame R, Lust JA, Hayman SR, Rajkumar SV, Zeldenrust SR, et al. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clinic Proceedings. PMID 28483059 DOI: 10.1016/j.mayocp.2017.02.016 |
0.178 |
|
| 2018 |
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, ... ... Zeldenrust SR, et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia. PMID 30258095 DOI: 10.1038/S41375-018-0258-Y |
0.178 |
|
| 2017 |
Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, et al. Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition. Annals of Medicine. 1-21. PMID 28271734 DOI: 10.1080/07853890.2017.1304649 |
0.17 |
|
| 2018 |
Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Peripheral Blood Biomarkers of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. American Journal of Hematology. PMID 30516847 DOI: 10.1002/Ajh.25365 |
0.169 |
|
| 2016 |
Muchtar E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Russell S, ... ... Zeldenrust S, et al. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings. 91: 1354-1361. PMID 27712634 DOI: 10.1016/j.mayocp.2016.06.027 |
0.165 |
|
| 2013 |
Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4529-35. PMID 24248686 DOI: 10.1200/Jco.2013.49.0086 |
0.165 |
|
| 2012 |
Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, Ando Y, Ikeda S, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Dyck PJ, Obici L, et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 19: 37-8. PMID 22551208 DOI: 10.3109/13506129.2012.678509 |
0.161 |
|
| 2009 |
Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clinic Proceedings. 84: 114-22. PMID 19181644 DOI: 10.4065/84.2.114 |
0.158 |
|
| 2017 |
Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Zeldenrust SR, et al. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation. PMID 29269795 DOI: 10.1038/S41409-017-0020-5 |
0.157 |
|
| 2007 |
Chahin N, Zeldenrust SR, Amrami KK, Engelstad JK, Dyck PJ. Two causes of demyelinating neuropathy in one patient: CMT1A and POEMS syndrome. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 34: 380-5. PMID 17803044 |
0.152 |
|
| 2020 |
Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, ... ... Zeldenrust S, et al. Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. PMID 32728185 DOI: 10.1038/S41375-020-0993-8 |
0.151 |
|
| 2011 |
Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 118: 2970-5. PMID 21690557 DOI: 10.1182/Blood-2011-04-348896 |
0.146 |
|
| 2008 |
Garces-Sanchez M, Dyck PJ, Kyle RA, Zeldenrust S, Wu Y, Ladha SS, Klein CJ. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle & Nerve. 37: 490-5. PMID 18236455 DOI: 10.1002/Mus.20955 |
0.146 |
|
| 2019 |
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, ... ... Zeldenrust S, et al. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 26: 101-102. PMID 31343331 DOI: 10.1080/13506129.2019.1582486 |
0.146 |
|
| 2009 |
Leung N, Saucier NA, Zeldenrust SR, Gunderson HD, Cornell LD. Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. Ndt Plus. 2: 292-4. PMID 25984018 DOI: 10.1093/ndtplus/sfp037 |
0.146 |
|
| 2008 |
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, et al. A novel report of cig-FISH and cytogenetics in POEMS syndrome. American Journal of Hematology. 83: 840-1. PMID 18839437 DOI: 10.1002/ajh.21285 |
0.14 |
|
| 2012 |
Loavenbruck AJ, Chaudhry V, Zeldenrust SR, Spinner RJ, Theis JD, Klein CJ. Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma. Muscle & Nerve. 46: 817-22. PMID 23055319 DOI: 10.1002/mus.23415 |
0.131 |
|
| 2011 |
D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 118: 4663-5. PMID 21881050 DOI: 10.1182/Blood-2011-06-362392 |
0.129 |
|
| 2011 |
Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, Ando Y, Ikeda SI, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Suhr OB. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 18: 196-7. PMID 21838485 DOI: 10.3109/13506129.2011.574354073 |
0.129 |
|
| 2004 |
Miller DV, McClure RF, Crawford BG, Zeldenrust SR, Leibovich BC, Sebo TJ. Histiocytes containing immunoglobulin crystals in the urine of a patient with IgA kappa plasmacytoma of the bladder. Diagnostic Cytopathology. 31: 48-51. PMID 15236265 DOI: 10.1002/dc.20083 |
0.126 |
|
| 2017 |
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, ... ... Zeldenrust SR, et al. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. Jama Oncology. PMID 28056114 DOI: 10.1001/Jamaoncol.2016.5763 |
0.126 |
|
| 2011 |
Donato LJ, Zeldenrust SR, Murray DL, Katzmann JA. A 71-year-old woman with multiple myeloma status after stem cell transplantation. Clinical Chemistry. 57: 1645-8. PMID 22125317 DOI: 10.1373/clinchem.2011.163766 |
0.124 |
|
| 2009 |
Kim DH, Zeldenrust SR, Low PA, Dyck PJ. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle & Nerve. 40: 363-70. PMID 19618439 DOI: 10.1002/Mus.21332 |
0.124 |
|
| 2006 |
Ladha SS, Dyck PJ, Spinner RJ, Perez DG, Zeldenrust SR, Amrami KK, Solomon A, Klein CJ. Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. Journal of the Peripheral Nervous System : Jpns. 11: 346-52. PMID 17117943 DOI: 10.1111/j.1529-8027.2006.00107.x |
0.122 |
|
| 2019 |
Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, ... ... Zeldenrust S, et al. Comparative analysis of staging systems in AL amyloidosis. Leukemia. PMID 30675009 DOI: 10.1038/S41375-018-0370-Z |
0.122 |
|
| 2004 |
Nepomuceno AI, Mason CJ, Muddiman DC, Bergen HR, Zeldenrust SR. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry. Clinical Chemistry. 50: 1535-43. PMID 15205369 DOI: 10.1373/clinchem.2004.033274 |
0.117 |
|
| 2008 |
Fervenza FC, Croatt AJ, Bittar CM, Rosenthal DW, Lager DJ, Leung N, Zeldenrust SR, Nath KA. Induction of heme oxygenase-1 and ferritin in the kidney in warm antibody hemolytic anemia. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 52: 972-7. PMID 18805612 DOI: 10.1053/j.ajkd.2008.07.012 |
0.112 |
|
| 1996 |
Hull MT, Waits RP, Uemichi T, Zeldenrust SR, Field L, Gofaeen MP, Season MD. Expression of amyloidogenic ser84 variant of human transthyretinc1tr in transgenic mice: Immunoelectron microscopic, immunohistochemical, and reverse transcription-polymerase chain reaction(RT-PCR) studies Faseb Journal. 10: A772. |
0.109 |
|
| 2016 |
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology. 68: 1014-20. PMID 27585505 DOI: 10.1016/j.jacc.2016.06.033 |
0.104 |
|
| 2014 |
Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. Jacc. Heart Failure. 2: 113-22. PMID 24720917 DOI: 10.1016/j.jchf.2013.11.004 |
0.094 |
|
| 2015 |
Lahoria R, Dyck PJ, Macon WR, Crum BA, Spinner RJ, Amrami KK, Zeldenrust SR, Tracy JA. Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum. Muscle & Nerve. PMID 25758704 DOI: 10.1002/mus.24646 |
0.09 |
|
| 2018 |
Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, ... ... Zeldenrust SR, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. PMID 29568092 DOI: 10.1038/S41375-018-0030-3 |
0.086 |
|
| 2017 |
Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS. Ocular Manifestations of Familial Transthyretin Amyloidosis. American Journal of Ophthalmology. PMID 29248199 DOI: 10.1016/j.ajo.2017.11.005 |
0.086 |
|
| 2010 |
Zeldenrust SR, Benson MD. Familial and Senile Amyloidosis Caused by Transthyretin Protein Misfolding Diseases: Current and Emerging Principles and Therapies. 795-815. DOI: 10.1002/9780470572702.ch36 |
0.085 |
|
| 2017 |
Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS. OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. Retina (Philadelphia, Pa.). PMID 29068915 DOI: 10.1097/IAE.0000000000001901 |
0.082 |
|
| 2003 |
Soares-Welch CV, Zeldenrust SR, Conover CA, Grant CS, Service FJ. Hodgkin's lymphoma manifesting with hypoglycemia. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 9: 96-7. PMID 12917097 DOI: 10.4158/EP.9.1.96 |
0.076 |
|
| 2015 |
Warsame R, Kasi PM, Villasboas-Bisneto JC, Gallenberg D, Wolf R, Ward J, Matt-Hensrud N, Grethen K, Colborn L, Zeldenrust S, Lacy MQ, Thompson CA. Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation. Journal of Oncology Practice / American Society of Clinical Oncology. PMID 26374861 DOI: 10.1200/JOP.2015.005785 |
0.07 |
|
| 2016 |
Chakraborty R, Gertz MA, Dispenzieri A, Gonsalves WI, Zeldenrust SR, Russell SJ, Go RS, Kapoor P, Rajkumar VS, Hayman SR, Hwa YL, Lacy MQ, Kyle RA, Leung N, Kumar SK. Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology. PMID 27328653 DOI: 10.1111/bjh.14205 |
0.06 |
|
| 2013 |
Zeldenrust SR, Brandt J, Hagan H, Witty E, Larson J, Pederson C, Herdahl L, Gallenberg D, Gronseth D, Spaulding T. Improving efficiencies in a hospital-based hematology outpatient service. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 165. PMID 28136395 DOI: 10.1200/jco.2013.31.31_suppl.165 |
0.053 |
|
| 2002 |
Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 4111-4. PMID 12351608 |
0.051 |
|
| 2013 |
Zeldenrust SR, Cooper LT. Getting to the heart of the matter: cardiac involvement in transthyretin-related amyloidosis. European Heart Journal. 34: 483-5. PMID 22927558 DOI: 10.1093/eurheartj/ehs238 |
0.051 |
|
| Hide low-probability matches. |